| 发明名称 | Use of annexin A3 as a diagnostic and prognostic biomarker and therapeutic target for treating hepatocellular carcinoma | ||
| 摘要 | Annexin A3 (ANAX3) is utilized as a biomarker for the diagnosis and prognosis of hepatocellular carcinoma (HCC) and the utilization of a monoclonal antibody against ANXA3 or antisense polynucleotide against ANXA3 mRNA for the suppression or treatment of HCC, alone or in combination with other HCC treatment. Monoclonal antibody against ANXA3 can be administered for the suppression of tumor growth, metastasis, and chemoresistance. | ||
| 申请公布号 | US9487831(B2) | 申请公布日期 | 2016.11.08 |
| 申请号 | US201414485206 | 申请日期 | 2014.09.12 |
| 申请人 | VERSITECH LIMITED | 发明人 | Ma Stephanie Kwai Yee;Tong Man;Guan Xin-Yuan |
| 分类号 | G01N33/574;C12Q1/68;C12N15/113;G01N33/50;C07K16/18 | 主分类号 | G01N33/574 |
| 代理机构 | Saliwanchik, Lloyd & Eisenschenk | 代理人 | Saliwanchik, Lloyd & Eisenschenk |
| 主权项 | 1. A method for detecting the presence of ANXA3 in a subject, the method comprising: (a) obtaining a biological sample from the subject, wherein the sample is liver tissue, liver cells, liver interstitial fluid, serum, or plasma; (b) contacting the biological sample with an antibody that specifically binds to a peptide consisting of the sequence of SEQ ID NO: 1; and (c) detecting the complex comprising ANXA3 protein and the antibody. | ||
| 地址 | Hong Kong CN | ||